Biotricity Earnings Call Transcripts
Fiscal Year 2026
-
A vertically integrated cardiac monitoring company has achieved profitability, high margins, and strong customer retention by offering a cellular-enabled, SaaS-based device that simplifies workflow and increases physician revenue. Expansion into disease management and implantable monitoring, along with strategic partnerships and a growing commercial team, are expected to drive future growth.
-
Revenue grew 10.2% year-over-year to $4M, with gross margin rising to 81.5% and positive EBITDA for the third consecutive quarter. The company expects continued revenue growth and aims for net income profitability in 2026, driven by strong adoption of its cardiac monitoring solutions.
-
Revenue grew 19% year-over-year to $3.9M, with gross margin rising to 81.9% and EBITDA positive for the second consecutive quarter. Strategic partnerships, product innovation, and commercial expansion are expected to drive continued growth and profitability.
-
Revenue grew 21% year-over-year to $3.9M, with gross margin rising to 80.5%. Achieved first-ever positive EBITDA of $333K and operating profit, while net loss narrowed significantly. Strategic partnerships and regulatory approvals support continued growth.
Fiscal Year 2025
-
Q3 2025 saw 21.7% revenue growth, record gross margins, and a 115% improvement in free cash flow. Strategic partnerships and new verticals are expanding market reach, with profitability and further margin gains expected as AI and international initiatives progress.
-
Q2 2025 saw 13% revenue growth, a 23% rise in gross profit, and a 57% reduction in net loss. Positive EBITDA was achieved for the first time, driven by operational efficiencies, strategic partnerships, and expanded market reach, with a clear path to profitability.
Fiscal Year 2024
-
Revenue grew 25% year-over-year to $12.06 million, with gross margin rising to 69.3%. Strategic partnerships, new product launches, and cost reductions have positioned the company for EBITDA breakeven later this year and continued margin improvement.